The two different profiles in heart failure with preserved ejection fraction and type 2 diabetes mellitus : ischemic and diabetic
OBJECTIVE: Two profiles of patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) can be discerned: those with ischemic and those with diabetic cardiomyopathy (DMC). We aim to analyze clinical differences and prognosis between patients of these two profiles.
MATERIAL AND METHODS: This cohort study analyzes data from the Spanish Heart Failure Registry, a multicenter, prospective registry that enrolled patients admitted for decompensated heart failure and followed them for one year. Three groups were created according to the presence of T2DM and heart disease depending on the etiology (ischemic when coronary artery disease was present, or DMC when no coronary, valvular, or congenital heart disease; no hypertension; nor infiltrative cardiovascular disease observed on an endomyocardial biopsy). The groups and outcomes were compared.
RESULTS: A total of 466 patients were analyzed. Group 1 (n = 210) included patients with ischemic etiology and T2DM. Group 2 (n = 112) included patients with DMC etiology and T2DM. Group 3 (n = 144), a control group, included patients with ischemic etiology and without T2DM. Group 1 had more hypertension and dyslipidemia; group 2 had more atrial fibrillation (AF) and higher body mass index; group 3 had more chronic kidney disease and were older. In the regression analysis, group 3 had a better prognosis than group 1 (reference group) for cardiovascular mortality and HF readmissions (HR 0.44;95%CI 0.2-1; p = .049).
CONCLUSIONS: Patients with T2DM and HFpEF, who had the poorest prognosis, were of two different profiles: either ischemic or DMC etiology. The first had a higher burden of cardiovascular disease and inflammation whereas the second had a higher prevalence of obesity and AF. The first had a slightly poorer prognosis than the second, though this finding was not significant.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Current medical research and opinion - 40(2024), 3 vom: 01. März, Seite 359-366 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arévalo Lorido, José Carlos [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Coronary artery disease |
|---|
| Anmerkungen: |
Date Completed 28.02.2024 Date Revised 19.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03007995.2024.2303089 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366840630 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366840630 | ||
| 003 | DE-627 | ||
| 005 | 20240420232219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03007995.2024.2303089 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1381.xml |
| 035 | |a (DE-627)NLM366840630 | ||
| 035 | |a (NLM)38193461 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arévalo Lorido, José Carlos |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The two different profiles in heart failure with preserved ejection fraction and type 2 diabetes mellitus |b ischemic and diabetic |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2024 | ||
| 500 | |a Date Revised 19.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: Two profiles of patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) can be discerned: those with ischemic and those with diabetic cardiomyopathy (DMC). We aim to analyze clinical differences and prognosis between patients of these two profiles | ||
| 520 | |a MATERIAL AND METHODS: This cohort study analyzes data from the Spanish Heart Failure Registry, a multicenter, prospective registry that enrolled patients admitted for decompensated heart failure and followed them for one year. Three groups were created according to the presence of T2DM and heart disease depending on the etiology (ischemic when coronary artery disease was present, or DMC when no coronary, valvular, or congenital heart disease; no hypertension; nor infiltrative cardiovascular disease observed on an endomyocardial biopsy). The groups and outcomes were compared | ||
| 520 | |a RESULTS: A total of 466 patients were analyzed. Group 1 (n = 210) included patients with ischemic etiology and T2DM. Group 2 (n = 112) included patients with DMC etiology and T2DM. Group 3 (n = 144), a control group, included patients with ischemic etiology and without T2DM. Group 1 had more hypertension and dyslipidemia; group 2 had more atrial fibrillation (AF) and higher body mass index; group 3 had more chronic kidney disease and were older. In the regression analysis, group 3 had a better prognosis than group 1 (reference group) for cardiovascular mortality and HF readmissions (HR 0.44;95%CI 0.2-1; p = .049) | ||
| 520 | |a CONCLUSIONS: Patients with T2DM and HFpEF, who had the poorest prognosis, were of two different profiles: either ischemic or DMC etiology. The first had a higher burden of cardiovascular disease and inflammation whereas the second had a higher prevalence of obesity and AF. The first had a slightly poorer prognosis than the second, though this finding was not significant | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Heart failure preserved ejection fraction | |
| 650 | 4 | |a coronary artery disease | |
| 650 | 4 | |a diabetic cardiomyopathy | |
| 650 | 4 | |a type 2 diabetes mellitus | |
| 700 | 1 | |a Carretero Gómez, Juana |e verfasserin |4 aut | |
| 700 | 1 | |a Conde Martel, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Aramburu Bodas, Oscar |e verfasserin |4 aut | |
| 700 | 1 | |a Trullás, Joan Carles |e verfasserin |4 aut | |
| 700 | 1 | |a Carrasco Sánchez, Francisco Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Manzano Espinosa, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Cerqueiro González, Jose Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno García, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Casado Cerrada, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Montero Pérez-Barquero, Manuel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medical research and opinion |d 1972 |g 40(2024), 3 vom: 01. März, Seite 359-366 |w (DE-627)NLM000081019 |x 1473-4877 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:359-366 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03007995.2024.2303089 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2024 |e 3 |b 01 |c 03 |h 359-366 | ||